Niktimvo
Payments companies reported to CMS as associated with Niktimvo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Niktimvo, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Niktimvo
These are the largest totals companies reported as associated with Niktimvo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Usama Gergis | Allentown, PA | Hematology & Oncology | $100,404.43 |
| Sam Penza | Columbus, OH | Hematology (Internal Medicine) | $71,050.83 |
| Sami Brake | Grand Rapids, MI | Medical Oncology | $68,265.71 |
| Salman Fazal | Pittsburgh, PA | Hematology & Oncology | $66,240.18 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $57,480.27 |
| Michael Bishop | Chicago, IL | Hematology & Oncology | $52,019.33 |
| Nosha Farhadfar | San Antonio, TX | Hematology & Oncology | $49,676.53 |
| Christopher Dandoy | Cincinnati, OH | Pediatric Hematology-Oncology | $46,197.20 |
| Amandeep Salhotra | Duarte, CA | Hematology (Internal Medicine) | $39,390.98 |
| Karolina Faysman | Los Angeles, CA | Adult Health (Nurse Practitioner) | $33,550.40 |
Prescribed Niktimvo?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.